Swedbank AB Raises Holdings in Insulet Co. (NASDAQ:PODD)

Swedbank AB increased its position in shares of Insulet Co. (NASDAQ:PODD) by 152.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 53,688 shares of the medical instruments supplier’s stock after buying an additional 32,456 shares during the period. Swedbank AB owned about 0.08% of Insulet worth $14,016,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Blue Trust Inc. increased its position in Insulet by 117.3% during the 4th quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier’s stock valued at $72,000 after purchasing an additional 149 shares during the period. Juncture Wealth Strategies LLC bought a new position in Insulet in the fourth quarter worth approximately $229,000. Geneos Wealth Management Inc. lifted its holdings in Insulet by 68.5% during the fourth quarter. Geneos Wealth Management Inc. now owns 30,126 shares of the medical instruments supplier’s stock worth $7,865,000 after buying an additional 12,244 shares during the period. Fifth Third Bancorp boosted its position in Insulet by 1.4% during the 4th quarter. Fifth Third Bancorp now owns 8,560 shares of the medical instruments supplier’s stock valued at $2,235,000 after acquiring an additional 116 shares in the last quarter. Finally, CX Institutional purchased a new position in shares of Insulet in the 4th quarter valued at $238,000.

Analyst Ratings Changes

PODD has been the topic of a number of recent research reports. Citigroup raised their price objective on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Morgan Stanley lifted their price objective on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Raymond James raised their target price on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. TD Cowen upped their price target on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. Finally, BTIG Research raised their price objective on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $272.81.

Insider Buying and Selling at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. This represents a 52.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

Insulet Stock Down 0.6 %

PODD stock opened at $278.38 on Friday. The company has a market capitalization of $19.53 billion, a P/E ratio of 47.67, a price-to-earnings-growth ratio of 3.48 and a beta of 1.22. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $286.39. The firm’s fifty day simple moving average is $268.69 and its 200-day simple moving average is $237.96. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 EPS for the quarter, beating the consensus estimate of $0.77 by $0.13. The company had revenue of $543.90 million for the quarter, compared to analyst estimates of $518.50 million. Insulet had a net margin of 21.22% and a return on equity of 27.98%. During the same period in the prior year, the company earned $0.71 earnings per share. As a group, equities research analysts forecast that Insulet Co. will post 3.22 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.